The issuer is solely responsible for the content of this announcement.

Get insights from Ligand Pharmaceuticals' Q2 2025 earnings—57% royalty revenue growth, raised guidance, and key partnerships driving long-term growth.

With strong total returns through mid-year and rate cuts on the horizon, high-quality bonds have once again proved their potential worth as a core portfolio anchor. Read more ...

Joining FinextraTV for their Future of Wealth Series, Waqar Chaudry, Head of Digital Assets, Financing and Securities ...